Supplementary Material for: Prognostic Value of miR-375 for Survival Outcomes in Various Cancers: A Systematic Review and Meta-Analysis

2018-01-23T14:03:45Z (GMT) by Dan B. Luo J. Li K. Chen S.
Background: miR-375 plays a role in tumor progression; however, its potential as a prognostic factor in cancer remains unclear. This meta-analysis assessed the value of miR-375 as a global prognostic biomarker in human cancer. Methods: A systematic literature review was performed to retrieve publications with relevant survival
data. Pooled hazard ratios (HRs) were calculated for low miR-375 expression. Publication bias was examined. Results: Data were extracted from 11 studies of 1,797 patients (low expression in 769 cases; high in 1,028 cases). The pooled HR for overall/cumulative survival (OS/CS) was 1.90 (95% confidence interval (CI) 1.57–2.29) and the pooled HR for disease-free, recurrence-free or progression-free survival (DFS/RFS/PFS) was 1.93 (95% CI 1.39–2.67), indicating low miR-375 expression was associated with significantly poorer outcomes compared to normal/high miR-375 expression. Subgroup analysis revealed miR-375 might be a good prognostic factor in cancer, regardless of population, sample type, and cancer type. The prognostic value of miR-375 in non-Chinese patients was particularly high (pooled HR > 2). Conclusion: Low miR-375 expression could represent a valuable prognostic marker in various cancers. Circulating miR-375 Levels may provide a useful non-invasive, practical prognostic
biomarker. However, the prognostic value of miR-375 in specific cancer types remains unclear; further studies are warranted.